Introduction
Tirzepatide vs semaglutide: two GLP-1 medicines, not one
Tirzepatide vs semaglutide is a choice between two GLP-1 medicines, not one: both have changed what’s possible in physician-supervised weight management, but they are not interchangeable. They act on different hormone pathways, they produced different average results in clinical trials, and their evidence bases answer different questions.
At Protocol Health in Scarsdale, NY, GLP-1 therapy is paired with labs, lifestyle guidance, and ongoing medical support so treatment decisions are personalized to your goals, health history, and response. This guide is educational and not medical advice.
See Which GLP-1 Is Right for YouQuick Answer
The biggest difference between tirzepatide and semaglutide
The biggest difference between tirzepatide and semaglutide is the number of hormone pathways they target. Semaglutide is a GLP-1 receptor agonist that helps regulate appetite, blood sugar, and digestion.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it targets two incretin pathways involved in appetite regulation and metabolic control. That makes tirzepatide a GLP-1 receptor agonist and a GIP receptor agonist; semaglutide is a different molecule that acts on GLP-1 alone.
On average, tirzepatide produced more weight loss than semaglutide in the one head-to-head obesity trial. Semaglutide has a large cardiovascular outcomes trial behind it in people without diabetes.
Neither option is universally better. The right choice depends on your biology, health history, treatment goals, tolerability, and provider guidance.
How They Work
How do tirzepatide and semaglutide work?
Tirzepatide and semaglutide work by mimicking gut hormones, and semaglutide mimics GLP-1 (glucagon-like peptide-1), a hormone the gut releases after eating. GLP-1 signals fullness to the brain, slows how quickly the stomach empties, and helps the pancreas release insulin when blood sugar rises. Semaglutide is sold as Wegovy for weight management and Ozempic for type 2 diabetes. Ozempic is a once-weekly injection. Wegovy's label now covers both a once-weekly injection and a once-daily tablet, the tablet carrying the adult weight-management and cardiovascular indications but not the pediatric or MASH ones.
Tirzepatide mimics GLP-1 and a second gut hormone, GIP (glucose-dependent insulinotropic polypeptide). Researchers think the added GIP signal contributes to appetite control and to how the body handles insulin and fat, although exactly how much it adds is still being studied. Tirzepatide is sold as Zepbound for weight management and Mounjaro for type 2 diabetes, also once weekly.
Both medications start at a low dose and step up over several weeks. That gradual titration lets the body adjust and is one of the main ways a physician limits side effects. In short, semaglutide works through one gut-hormone signal and tirzepatide through two.
Comparison
Tirzepatide vs Semaglutide: Side-by-Side Comparison
The table below compares tirzepatide and semaglutide on the points patients ask about most. Trial figures come from the brand-name medications.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Receptors targeted | GIP and GLP-1 (dual agonist) | GLP-1 only |
| Brand names | Zepbound (weight), Mounjaro (diabetes) | Wegovy (weight), Ozempic (diabetes) |
| How it is taken | Once-weekly injection | Once-weekly injection, or a once-daily Wegovy tablet |
| Average weight loss, SURMOUNT-5 (72 weeks) | 20.2% | 13.7% |
| Cardiovascular outcomes trial without diabetes | Dedicated trial (SURMOUNT-MMO) under way | SELECT: 20% lower risk of major cardiac events vs placebo |
| Most common side effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, constipation, vomiting |
Protocol Health evaluates labs, medical history, contraindications, and lifestyle context before recommending a medication pathway.
Effectiveness
Which GLP-1 helps you lose more weight: tirzepatide or semaglutide?
Of the two GLP-1 medicines, tirzepatide helps you lose more weight than semaglutide on average, and the best evidence for that is a direct comparison. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, 751 adults with obesity but without type 2 diabetes received the highest dose they could tolerate of either tirzepatide or semaglutide for 72 weeks. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide, and waist circumference fell by 18.4 cm versus 13.0 cm. The trial was open-label and funded by Eli Lilly, which makes tirzepatide.
The placebo-controlled trials point the same way. In STEP 1, adults taking semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. In SURMOUNT-1, tirzepatide produced average losses of 15.0% to 20.9% over 72 weeks depending on dose, compared with 3.1% on placebo.
On average weight loss, the data favor tirzepatide. But averages hide wide individual ranges. Some people lose more on semaglutide, some tolerate one far better than the other, and safety, side effects, access, and medical history matter as much as the headline number.
Cardiometabolic Benefits
Semaglutide vs tirzepatide benefits beyond the scale
Beyond the scale, semaglutide and tirzepatide both have benefits, and semaglutide has the stronger cardiovascular outcomes evidence in people without diabetes. The SELECT trial enrolled 17,604 adults aged 45 or older with existing cardiovascular disease and overweight or obesity. Over a mean follow-up of about 40 months, heart attack, stroke, or cardiovascular death occurred in 6.5% of people on semaglutide versus 8.0% on placebo, a 20% relative reduction.
Tirzepatide also improves blood sugar, blood pressure, and lipid markers in trials. In people with type 2 diabetes, the SURPASS-2 trial found tirzepatide lowered HbA1c and body weight more than semaglutide 1 mg over 40 weeks. For someone whose main concern is established heart disease, that difference in evidence can shape the choice.
Side Effects and Safety
Tirzepatide vs semaglutide side effects
Tirzepatide and semaglutide share a similar side-effect profile. The most common effects are gastrointestinal: nausea, diarrhea, constipation, and vomiting, usually mild to moderate and most frequent while the dose is being increased. In SURMOUNT-5, gastrointestinal events were the most common adverse events in both groups.
Both medications carry a boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Pancreatitis, gallbladder problems, and low blood sugar when combined with certain diabetes medications are less common but serious risks.
Trial results describe the brand-name medications. Compounded semaglutide and tirzepatide are not FDA-approved, are not the same as the brand-name products, and were not studied in these trials. A physician should review your history, current medications, and labs before either one is prescribed.
Switching
Can you switch from semaglutide to tirzepatide?
Patients switch from semaglutide to tirzepatide for several reasons, usually a plateau, side effects, or a change in coverage. It is a physician decision, not a simple swap. No randomized trial has tested switching after a plateau; SURMOUNT-5 compared people who started each drug fresh, so the benefit of switching is an individual judgment rather than a proven result. There is no official one-to-one dose conversion between the two medications, so a provider chooses a starting dose of the new medication based on your current dose, how you tolerated it, and how long you have been on it.
Switching in the other direction, from tirzepatide to semaglutide, follows the same logic. If you are considering a change, bring your dose history and recent labs to the conversation, and do not stop or restart either medication on your own. Our guide to GLP-1 and muscle loss covers what to protect while you are on either one.
Good Candidates
Who might suit tirzepatide or semaglutide?
Tirzepatide or semaglutide might suit adults with obesity, or with overweight plus a weight-related condition such as high blood pressure or prediabetes, and both are considered only after a full medical evaluation.
A physician may lean toward tirzepatide when the priority is maximum average weight loss and there is no reason to avoid it. A physician may lean toward semaglutide when established cardiovascular disease is part of the picture, or when a patient has already done well on it. Tolerability, other medications, and access often decide the rest.
For a broader view of how these medications fit into a plan, see our medical weight loss program and our explainer on compounded vs brand-name GLP-1 medications. Which medication suits you is a physician's call based on your goals, heart health and tolerance.
The Protocol Approach
How Protocol Health helps you choose between tirzepatide and semaglutide
Protocol Health helps you choose between tirzepatide and semaglutide as a physician-led clinic that sees patients in person in Scarsdale, NY, and by telehealth across NY, NJ, CT, FL and CA. Our team treats the tirzepatide vs semaglutide question as a clinical decision built on your labs, history, and goals, not on headlines.
In Protocol Health’s medical weight loss program, care begins with a consultation and, in most cases, baseline labs. If a GLP-1 medication is appropriate, your provider starts low, titrates gradually, and follows up regularly to manage side effects and protect muscle. Learn more about tirzepatide at Protocol Health or semaglutide at Protocol Health, or take the quiz to see where to start.
The bottom line on tirzepatide vs semaglutide: tirzepatide produced more average weight loss in the only head-to-head obesity trial, semaglutide has the dedicated cardiovascular outcomes trial in people without diabetes, and your history, tolerance and goals decide which one fits.
FAQ
Frequently Asked Questions
Is tirzepatide better than semaglutide?
For average weight loss, the evidence favors tirzepatide: in the SURMOUNT-5 head-to-head trial, adults lost 20.2% of body weight on tirzepatide versus 13.7% on semaglutide over 72 weeks. Semaglutide has a dedicated cardiovascular outcomes trial in people without diabetes. Which is better for you depends on your health history, tolerability, and goals.
What is the difference between semaglutide and tirzepatide?
Semaglutide activates one gut-hormone receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP. Both are once-weekly injections that reduce appetite and improve blood sugar control, and both are prescribed by a physician after an evaluation.
Are tirzepatide side effects worse than semaglutide side effects?
The side-effect profiles are similar. Nausea, diarrhea, constipation, and vomiting are the most common with both, mostly mild to moderate and most frequent during dose increases. Individual tolerance varies, which is why gradual titration and follow-up matter.
Can you switch from semaglutide to tirzepatide?
Yes, under physician supervision. There is no official one-to-one dose conversion, so a provider chooses the starting dose of the new medication based on your current dose and how you tolerated it. Do not stop or switch medications on your own.
Is semaglutide the same as tirzepatide?
No. They are different molecules made by different companies. Semaglutide is sold as Wegovy and Ozempic; tirzepatide is sold as Zepbound and Mounjaro. Compounded versions of either are not FDA-approved.
Can I get tirzepatide or semaglutide through telehealth?
Protocol Health offers GLP-1 care in person in Scarsdale and by telehealth across NY, NJ, CT, FL, and CA. Every plan starts with a consultation and appropriate lab work. This is educational information, not medical advice.
Explore